- Home
- VOR vs GALT Comparison
VOR vs GALT Comparison
Compare VOR & GALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VOR
- GALT
- Stock Information
- Founded
- VOR 2015
- GALT 2000
- Country
- VOR United States
- GALT United States
- Employees
- VOR N/A
- GALT N/A
- Industry
- VOR Biotechnology: Pharmaceutical Preparations
- GALT Biotechnology: Pharmaceutical Preparations
- Sector
- VOR Health Care
- GALT Health Care
- Exchange
- VOR Nasdaq
- GALT Nasdaq
- Market Cap
- VOR 207.1M
- GALT 232.3M
- IPO Year
- VOR 2021
- GALT N/A
- Fundamental
- Price
- VOR $29.40
- GALT $5.06
- Analyst Decision
- VOR Buy
- GALT Strong Buy
- Analyst Count
- VOR 6
- GALT 3
- Target Price
- VOR $85.33
- GALT $6.00
- AVG Volume (30 Days)
- VOR 526.1K
- GALT 247.4K
- Earning Date
- VOR 11-06-2025
- GALT 11-12-2025
- Dividend Yield
- VOR N/A
- GALT N/A
- EPS Growth
- VOR N/A
- GALT N/A
- EPS
- VOR N/A
- GALT N/A
- Revenue
- VOR N/A
- GALT N/A
- Revenue This Year
- VOR N/A
- GALT N/A
- Revenue Next Year
- VOR N/A
- GALT N/A
- P/E Ratio
- VOR N/A
- GALT N/A
- Revenue Growth
- VOR N/A
- GALT N/A
- 52 Week Low
- VOR $2.62
- GALT $0.73
- 52 Week High
- VOR $65.80
- GALT $6.55
- Technical
- Relative Strength Index (RSI)
- VOR 52.41
- GALT 64.51
- Support Level
- VOR $28.65
- GALT $4.89
- Resistance Level
- VOR $31.31
- GALT $5.25
- Average True Range (ATR)
- VOR 3.26
- GALT 0.27
- MACD
- VOR -1.89
- GALT 0.03
- Stochastic Oscillator
- VOR 2.79
- GALT 79.34
About VOR Vor Biopharma Inc.
Vor Biopharma Inc is a clinical stage cell therapy company. It combines a novel patient engineering approach with targeted therapies to provide a solution for patients suffering from hematological malignancies. The company's products include VCAR33, Tremcel and Myelodysplastic Syndrome, Trem-cel+VCAR33 Treatment System, VADC45, CD123, CLL1, EMR2.
About GALT Galectin Therapeutics Inc.
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.